Homocysteine. Laboratory aspects of clinical application
https://doi.org/10.33667/2078-5631-2025-22-43-47
Abstract
Numerous studies have confirmed the role of homocysteine as a marker of the risk of developing and adverse outcome of cardiovascular, neurodegenerative, oncological diseases and pregnancy. Quantitative criteria for homocysteinemia are used in clinical practice. The results obtained using different diagnostic systems and options for conducting the preanalytical stage may vary. The immunochemical methods discussed in the article generally demonstrate acceptable reproducibility and precision in measuring homocysteine concentrations. To assess the degree of harmonization of various methods, including enzymatic ones, it is necessary to introduce specialized external quality assessment programs and interlaboratory comparison systems with open access to their analytical reports into the practice of medical laboratories.
About the Authors
N. A. Kovyazina
Nikiforov Russian Center of Emergency and Radiation Medicine
Russian Federation
Russian Federation
Kovyazina Nadezhda A., DM Sci (habil.), head of Laboratory of Serological Research and Allergy Diagnostics
Saint-Petersburg
N. A. Alkhutova
Nikiforov Russian Center of Emergency and Radiation Medicine
Russian Federation
Russian Federation
Alkhutova N.A., PhD Bio Sci., senior researcher at Laboratory of Clinical Laboratory Dept
Saint-Petersburg
O. L. Zhizhina
St. Petersburg State University
Russian Federation
Russian Federation
Zhyzhina O.L., PhD Med, Associate Professor of the Department of Propaedeutics of Internal Dis-eases
Saint-Petersburg
References
1. Hyperhomocysteinemia in liver cirrhosis: mechanisms and role in vascular and hepatic fibrosis / E. R. Garcia-Tevijano, C. Berasain, J. A. Rodriguez, F. J. Corrales, R. Arias, A. Martin-Duce, J. Caballeria, J. M. Mato, M. A. Avila. // Hypertension. – 2001. – Vol.38. – № 5. – P. 1217–1221. DOI:10.1161/hy1101.099499.
2. Lebedeva А. Yu. Гипергомоцистеинемия: современный взгляд на проблему/ А. Yu. Lebedeva, К. V. Mihailova // Russian Journal of Cardiology. – 2006. – P. 149–157. (In Russ.) DOI: 10.15829/1560-4071-2006-0-149-157
3. Lentz, S. R. Homocysteine: Is it a clinically important cardiovascular risk factor? // S. R. Lentz, W. G. Haynes // Cleveland Clinic journal of medicine. – Vol. 71. – № 9. – P. 729–734. DOI:10.3949/ccjm.71.9.729
4. Uel, P. M. Plasma homocysteine, a risk factorfor vascular disease plasma levels in health, disease, and drug therapy / P. M. Uel, H. Refsum // Мedicine. – 1989. – Р.114–501.
5. Relation of plasma total homocysteine to cardiovascular mortality in a French population/ J. Blacher, A. Benetos, J. Kirzin, A. Malmejac, L. Guize, M. E. Safar// American Journal of cardiology. – 2002. – Vol. 90. – № 6. – P. 591–595. DOI: 10.1016/S00002–9149(02)02561-4.
6. Homocysteine and risk of cardiovascular disease / F. Andreotti, F. Burzotta, A. Manzoli, K. Robinson // The Journal of Thrombosis and Thrombolysis. – 2000. – Vol. 9. – № 1. – P. 13–21. DOI: 10.1023/a:1018675624181.
7. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. Homocysteine Studies Collaboration // The Journal of the American Medical Association. – 2002. – Vol. 288. – № 1. P. 2015–2022. DOI:10.1001/jama.288.16.2015
8. Plasma total homocysteine and cardiovascular and noncardiovascular mortality: the Hordaland Homocysteine Study/ S. E. Vollset, H. Refsum, A. Tverdal, O. Nygard, J. E. Nordrehaug, G. S. Tell, P. M. Ueland // The American journal of clinical nutrition. – 2001. –Vol. 74. – № 1. – P. 130–136. DOI:10.1093/ajcn/74.1.130
9. Diagnostic value of joint detection of homocysteine and RDW CV on acute miocardial infarction / G. Hu, J. Zhang, Y. G. Tian, Y. H. Li, L. You, L. J. Qiao // European Review for Medical and Pharmacological Sciences. – 2016. – Vol. 20. – № 19. – P. 4124–4128.
10. Medvedev, D. V. Molecular mechanisms of homocysteine’s toxic action / D. V. Medvedev, V. I. Zvyagina // Russian cardiology bulletin. – 2017. – Vol. 12. – № 1. – P. 52–576. (In Russ.)
11. Maslov, А. P. Hyperhomocysteinaemia and increased risk of cardio-vascular complications in patients having ischemic heasrt disease with atherogenic hypercholesterolemia / A. P. Maslov, A. T. Teplyakov, A. V. Kouznetsova // Siberian Scientific Medical Journal. – 2009. – № 4. – С. 18–24. (In Russ.)
12. Inflammatory markers, endothelial function and cardiovascular risk / B. C. Teixeira, A. L. Lopes, R.C.O. Macedo, C. S. Correa, T. R. Ramis, J. L. Ribeiro, Oliveira A. Reischak // The Jornal Vascular Brasileiro. – 2014. – Vol. 132. – P. 108–115.
13. Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease / S. Seshadri, A. Beiser, J. Selhub, P. F. Jacques, I. H. Rosenberg, R. B. D’Agostino, P. W. Wilson, P. A. Wolf // The New England journal of medicine. – 2002. – Vol. 346. – № 7. – P. 476–483. DOI: 10.1056/NEJMoa011613.
14. The Hordaland Homocysteine Study: a community-based study of homocysteine, its determinants, and associations with disease / H. Refsum, E. Nurk, A. D. Smith, P. M. Ueland, C. G. Gjesdal, I. Bjelland, A. Tverdal, G. S. Tell, O. Nygard, S. E. Vollset // The Journal of Nutrition. – 2006. – Vol. 136. – № 6. – P. 1731S-1740S. DOI: 10.1093/jn/136.6.1731S.
15. Van Guldener, C. Hyperhomocysteinaemia in chronic kidney disease: focus on transmethylation / C. Van Guldener, F. Stam, C. D. Stehouwer // Clinical chemistry and laboratory medicine. – 2005. – Vol. 43. – № 10. – P. 1026–1031. DOI: 10.1515/CCLM.2005.180
16. European guidelines on cardiovascular disease prevention in clinical practice (2012) // Russian Journal of Cardiology. 2012. – № 4s2 – P. 4–84. (In Russ.).
17. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC) // European Heart Journal. 2021. – Vol. 42. – № 34. – P. 3227–3337. DOI: 10.1093/eurheartj/ehab484.
18. Сardiovascular prevention 2017. National guidelines. // Russian Journal of Cardiology. – 2018. – Vol. 23. – № 6. (In Russ.). DOI: 10.15829/1560-4071-2018-6-7-122.
19. Eurasian Association of Cardiology (EAC)/ Russian National Atherosclerosis Society (RNAS) Guidelines for the diagnosis and correction of dyslipidemia for the prevention and treatment of atherosclerosis (2020)/ Valery V. Kukharchuk, Marat V. Ezhov, Igor V. Sergienko, Grigory G. Arabidze, Tatyana V. Balakhonova, Victor S. Gurevich, Parunak A. Zelveyan, Tulkun M. Murataliev, Gulzhan Sh. Myrzakhmetova, Olga A. Sudzhaeva, Alexander B. Shek, Vasadat A. Azizov, Natalya B. Gornyakova, Michael A. Kachkovsky, Pavel P. Malyshev, Sergei N. Pokrovsky, Igor V. Sergienko, Alexey A. Sokolov, Alexander B. Sumarokov, Andrei G. Obrezan, Igor I. Shaposhnik // Eurasian heart journal. – 2020. – № 2. – P. 6–29. (In Russ.). DOI:10.38109/2225-1685-2020-2-6-29
20. Andersson, A. Homocysteine export from erythrocytes and its implication for plasma sampling / A. Andersson, A. Isaksson, B. Hultberg // Clinical chemistry – 1992. – Vol. 38. – № 7. – P. 1311–1315.
21. Metabolomics of ADSOL (AS-1) red blood cell storage / J. D. Roback, C. D. Josephson, E. K. Waller, J. L. Newman, S. Karatela, K. Uppal, D. P. Jones, J. C. Zimring, L. J. Dumont // Transfusion medicine reviews. 2014. Vol. 28. – № 2. – P. 41–55. DOI: 10.1016/j.tmrv.2014.01.003.
22. Klinicheskaya laboratornaya diagnostika: nacional’noe rukovodstvo. – Vol I./ed. V. V. Dolgov, V. V. Menshikov. – Moscow: GEOTAR-Media, 2012. – 928 p. (In Russ.)
23. GOST R 53079.4–2008. Quality assurance of clinical laboratory tests. Part 4. Rules for conducting of preanalytical stage. – Moscow: Standartinform, 2009. – 65 p. (In Russ.).
24. Tietz clinical quide to laboratory tests. Fourth edition / Aian H. B.; transl. V. V. Menshikov. – Moscow: Labora, 2013. – 1280 p.; ISBN 978-5-903284-12-2. (In Russ.)
25. Kovyazina, N. A. Laboratornye aspekty standartizacii preanaliticheskogo etapa issledovaniya gomocisteina / N/A/ Kovyazina, N. A. Alkhutova // Spravochnik zaveduyushchego KDL. – 2017. – № 11. – P. 20–32. (In Russ.).
26. Commutability of NIST SRM 1955 Homocysteine and Folate in Frozen Human Serum with selected total homocysteine immunoassays and enzymatic assays / B. C. Nelson, C. M. Pfeiffer, M. Zhang, D. L. Duewer, K. E. Sharpless, K. A. Lippa // Clinica chimica acta; international journal of clinical chemistry. – 2008. Voi. 395. – № 1–2. – P. 99–105. DOI: 10.1016/j.cca.2008.05.016.
27. GOST R ISO 5725-6-2002. Accuracy (trueness and precision) of measurement methods and results. Part 6. Use in practice of accuracy values. – Moscow. Standartinform. 2009. – 42 p. (In Russ.). 28. Ковязина, Н. А. Биологическая вариация – вклад в клиническую неопределенность и роль в обеспечении качества количественных лабораторных исследований / Н. А. Ковязина, Н. А. Алхутова, С. С. Алексанин // Менеджмент качества в медицине. – 2023. – № 3. – С. 101–107. Kovyazina, N. A. Biological variation – contribution to clinical uncertainty and role in quality ensuring of quantitative laboratory studies / N. A. Kovyazina, N. A. Alkhutova, S. S. Aleksanin // Quality management in medicine. – 2023. – № 3. – P. 101–107. (In Russ.).
28. Kovyazina, N. A. Biological variation – contribution to clinical uncertainty and role in quality ensuring of quantitative laboratory studies / N. A. Kovyazina, N. A. Alkhutova, S. S. Aleksanin // Quality management in medicine. – 2023. – № 3. – P. 101–107. (In Russ.).
Review
For citations:
Kovyazina N.A., Alkhutova N.A., Zhizhina O.L. Homocysteine. Laboratory aspects of clinical application. Medical alphabet. 2025;(22):43-47. (In Russ.) https://doi.org/10.33667/2078-5631-2025-22-43-47
Views:
80
Email this article 